cholestane-3,5,6-triol has been researched along with Epilepsy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Chen, Y; Duan, S; Huang, J; Leng, T; Lin, S; Tang, L; Yan, G; Yan, M; Yin, W; Zheng, G; Zhu, W | 1 |
| Chen, W; Hu, H; Huang, Y; Leng, T; Lu, B; Qiu, P; Su, X; Sun, H; Tang, L; Wang, Y; Yan, G; Yan, M; Yin, W; Zhang, J; Zhou, Y; Zhu, W | 1 |
2 other study(ies) available for cholestane-3,5,6-triol and Epilepsy
| Article | Year |
|---|---|
Cholestane-3β, 5α, 6β-triol suppresses neuronal hyperexcitability via binding to voltage-gated sodium channels.
Topics: Action Potentials; Animals; Binding Sites; Cells, Cultured; Cholestanols; Dose-Response Relationship, Drug; Epilepsy; Hippocampus; Ion Channel Gating; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Neurons; Neuroprotective Agents; Protein Binding; Protein Conformation; Rats; Rats, Sprague-Dawley; Treatment Outcome; Voltage-Gated Sodium Channels | 2018 |
Cholesterol metabolite cholestane-3β,5α,6β-triol suppresses epileptic seizures by negative modulation of voltage-gated sodium channels.
Topics: Animals; Anticonvulsants; Cholestanols; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Excitatory Amino Acid Agonists; Kainic Acid; Mice; Voltage-Gated Sodium Channel Blockers; Voltage-Gated Sodium Channels | 2015 |